MCC Releases Set of Nine Portfolio-Level Milestone and SUSAR “Timeliness” Performance Metrics
Carmel, IN, December 1, 2017-The Metrics Champion Consortium’s (MCC) Vendor Oversight Work Group has published its first set of portfolio-level metrics designed to answer high-priority vendor performance questions related to achieving timeliness goals. Specifically, the five performance metrics report whether 10 study milestones are achieved by established milestone dates. The group explored different data aggregation options and decided to define metrics that help answer the following Key Performance Questions:
Are milestones being delivered “on-time” across active studies?
Are milestones being delivered “on-time” across studies over a three-month period?
Are milestones being delivered “on-time” within each study phase (start-up, conduct,
closeout)?
“The new consensus-based portfolio-level milestone metrics represent a significant expansion of MCC’s extensive catalogue of metric definitions,” said Linda Sullivan, Co-Founder & President of MCC. “The MCC Vendor Oversight Work Group defined 10 study milestones and considered the pros and cons of different metric aggregation models when developing the metric set. We look forward to the release of additional portfolio-level vendor oversight quality, cost and relationship metrics in 2018.”
Additionally, the group defined four performance metrics measuring the timeliness of SUSAR reporting.
Each metric definition includes 15 components, including metric formula, data definitions and performance targets. MCC members are invited to visit the member portal to download the metric toolkit.
The Vendor Oversight Work Group is now exploring options for measuring sponsor/vendor relationships.
Two White Papers detailing the Vendor Oversight Work Group’s metric development process and the group’s overall approach are now available to download on the Vendor Oversight Work Group page on the MCC website.
About Metrics Champion Consortium
MCC is a trusted partner in the clinical trials industry to identify what to measure and assess the critical components of what is changing and how the industry is responding to address the changes to make improvements. We continually bring you new insights into the leading trends within the industry. For more information, please visit www.metricschampion.org.
Contact:
Jane Jones
MCC Marketing Manager
jjones@metricschampion.org
(317) 622-0266 ext. 110
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
